A carregar...
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Molecular Diversity Preservation International (MDPI)
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3742227/ https://ncbi.nlm.nih.gov/pubmed/23880851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms140713958 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|